Bausch Health (BHC) Q3 2024 Earnings Transcript

Bausch Health reported its sixth straight quarter of year-over-year growth excluding Bausch + Lomb, with Q3 revenue up 7% reported/8% organic and adjusted EBITDA up 9% to $723 million. Management raised full-year guidance, including organic growth to 4%-6%, adjusted EBITDA to $2.425 billion-$2.475 billion, and adjusted operating cash flow to $975 million-$1.025 billion, while adjusted gross margin guidance rose to about 81%. Offsetting the strong results are ongoing XIFAXAN patent litigation and the need for substantial debt reduction ahead of expected loss of exclusivity around 2028.

Analysis

The market is still underpricing how much of the current earnings power is becoming self-funded, not just operationally improved. The key second-order effect is that stronger cash conversion and margin expansion reduce refinancing pressure well before the XIFAXAN cliff, which should compress the probability of a distressed-capital-structure outcome more than the equity currently implies. That matters because the stock is still trading like a binary legal/timeline story, while management is increasingly executing like a cash compounder with optionality.

The real competitive asymmetry is in commercialization efficiency. The AI-targeting initiative and opportunistic supply capture suggest Bausch is building a lower-cost, higher-yield revenue engine that can partially offset eventual exclusivity decay; competitors facing tighter pricing or weaker supply should see share leakage in niche branded channels, especially where Bausch can flex manufacturing faster than larger peers. The risk is that this is a temporary peak-margin period: if channel inventory normalizes, one-off supply opportunities fade, and operating expense discipline slips, the current run-rate can look better than the medium-term earnings base.

The legal setup remains the main catalyst stack, but the market may be anchoring to the wrong date. Even if exclusivity survives into 2028, the equity reaction should increasingly be driven by financing math: every incremental quarter of cash flow meaningfully changes what level of debt is sustainable post-LOE. Conversely, if litigation news turns adverse, the equity could re-rate sharply because the market is not paying for a robust post-XIFAXAN bridge yet; that makes this a high-beta, event-driven long that should be expressed with defined downside.

Most importantly, the optionality is now more credible because management is simultaneously de-risking the balance sheet and advancing a new growth leg in Red Sea. The consensus seems to be treating Red Sea and the broader pipeline as “nice to have,” but if even one of these assets creates a late-decade growth bridge, the terminal value framework changes materially. That makes the setup asymmetric: near-term results can continue to beat, while the main downside is concentrated in a few legal and execution milestones over the next 6-18 months.

Key Decisions for Investors

• Long BHC common into the next 1-2 quarters on balance-sheet de-risking and guidance revision momentum; target a 12-18 month hold, with upside if cash flow continues to outpace maturities and downside defined by XIFAXAN litigation headlines.
• Buy BHC Jan-2026 or Jan-2027 out-of-the-money calls to express the legal-optionalty/cash-flow bridge with limited premium at risk; best risk/reward if you expect another 2-3 quarters of execution beats before litigation clarity improves.
• Pair trade: long BHC / short TEVA over 6-12 months, since BHC’s cash generation and margin trajectory are improving while TEVA remains more exposed to generic pricing pressure and less insulated by an IP-dependent bridge.
• For event risk, hedge any BHC equity long with short-dated puts around key litigation dates; the stock’s main drawdown risk is binary and can gap faster than the operational thesis can re-rate.
• If BLCO separation headlines accelerate, consider a tactical long BHC vs short BLCO basket only if the transaction structure preserves balance-sheet optionality; otherwise avoid the trade because tax and capital-allocation uncertainty can swamp the thesis.